Research Topics
| N J VogelzangSummaryAffiliation: University of Chicago Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaNicholas J Vogelzang
University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA
J Clin Oncol 21:2636-44. 2003..We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone...- A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinomaNicholas J Vogelzang
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
Cancer 100:65-71. 2004.... - A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancerN J Vogelzang
Cancer Research Center, University of Chicago, IL 60637 1470, USA
Invest New Drugs 19:255-60. 2001..No responses were seen in 14 patients. The median survival from on study was 16 months (range two to 28 months). At this dose and schedule ranpirnase has minimal activity in metastatic renal cell cancer... - Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignanciesS Mani
University of Chicago Medical Center, Section of Hematology Oncology, Chicago, Illinois, USA
Cancer 92:1567-76. 2001..The purpose of this study was to determine the maximum tolerated dose and toxicity profile of gemcitabine given on a weekly schedule with continuous infusion 5-fluorouracil... - Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago ExperienceA S Artz
University of Chicago Hospitals, Chicago, IL 60637 1470, USA
Bone Marrow Transplant 35:253-60. 2005..002). NST leads to durable responses in a minority of metastatic RCC patients. Appropriate patient selection is paramount. Anemia and decreased performance status may enable risk stratification... - Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancerB I Rini
Section of Hematology Oncology, University of Chicago Hospitals, IL 60637 1470, USA
J Clin Oncol 18:2419-26. 2000..To determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5-FU) in patients with metastatic renal cell carcinoma (RCC)... - Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancerR L Schilsky
Department of Medicine, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Illinois 60637, USA
Clin Cancer Res 6:3025-31. 2000..Bone marrow suppression, which may be cumulative, is the dose-limiting toxicity of the combination. Prolonged AGT suppression is likely attributable primarily to the effect of O6-benzyl-8-oxoguanine... - Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendationsB C Goh
Section of Hematology/Oncology, Cancer Research Center, University of Chicago, Chicago, IL, USA
J Clin Oncol 19:1476-84. 2001..CONCLUSION: The recommended dose for ZD9331 on this schedule is 25 mg/d. Neutropenia, thrombocytopenia, and rash were dose-limiting, and efficacy studies in colorectal cancer are indicated... - Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanomaM Aklilu
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
Ann Oncol 15:1109-14. 2004.... - A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabineS D Undevia
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
Ann Oncol 15:1705-11. 2004..CONCLUSIONS: The recommended phase II dose is 6 mg/m2 (or 10 mg) of CI-994 in combination with capecitabine 2000 mg/m2/day for 2 weeks of a 3-week cycle... - Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancerN J Vogelzang
Cancer Research Center, University of Chicago Pritzker School of Medicine, Illinois 60637 1470, USA
Clin Cancer Res 4:929-34. 1998..Curiously, an increase in alkaline phosphatase was associated with an increase in the platelet nadir (P = 0.02). If PZDH continues to be developed as an antineoplastic agent, further studies of these relationships are suggested... - Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinomaW M Stadler
Department of Medicine, University of Chicago, IL 60637, USA
J Clin Oncol 16:1820-5. 1998.... - Study of cohort-specific consent and patient control in phase I cancer trialsC K Daugherty
Department of Medicine, The MacLean Center for Clinical Medical Ethics, University of Chicago, IL 60637 1470, USA
J Clin Oncol 16:2305-12. 1998.... - Kidney cancerN J Vogelzang
University of Chicago Medical Center, Section of Hematology Oncology, IL 60637 1470, USA
Lancet 352:1691-6. 1998..Therapy for metastatic renal cancer remains inadequate, but recent developments in basic and clinical research suggest future improvement... - Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium studyW M Stadler
University of Chicago and University of Illinois, Chicago, IL, USA
J Clin Oncol 18:371-5. 2000..Because responses were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of flavopiridol in this patient population... - A phase II trial of oral temozolomide in patients with metastatic renal cell cancerD K Park
Department of Medicine, University of Chicago, Chicago, IL 60637, USA
Cancer Chemother Pharmacol 50:160-2. 2002..High AGT activity was observed in all four biopsies analyzed. CONCLUSIONS: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor... - Docetaxel and exisulind in hormone-refractory prostate cancerC W Ryan
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA
Semin Oncol 28:56-61. 2001..Accrual is ongoing... - High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234N J Vogelzang
University of Chicago, Department of Medicine, IL, USA
Ann Oncol 10:597-600. 1999..New agents with activity in mesothelioma are sorely needed. The Cancer and Leukemia Group B (CALGB) therefore performed a phase II study of high-dose paclitaxel in patients with malignant mesothelioma who had no prior chemotherapy... - Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancerR B Ewesuedo
Committee on Clinical Pharmacology, Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Chicago, IL 60637, USA
J Clin Oncol 19:2084-90. 2001..Further studies to characterize the pharmacodynamics and pharmacogenetics of TAS-103 are warranted... - Gemcitabine in the treatment of bladder cancerC W Ryan
Section of Hematology Oncology, University of Chicago Medical Centre, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Expert Opin Pharmacother 1:547-53. 2000..A randomised trial of gemcitabine plus cisplatin versus M-VAC has completed accrual but has not yet been reported. New combination studies of gemcitabine with other chemotherapy agents, including the taxanes, are ongoing... - A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumorsA A Desai
Section of Hematology and Oncology, University of Chicago, Chicago, IL 60637, USA
Ann Oncol 16:958-65. 2005..CONCLUSIONS: The recommended dose of GTI-2040 given on this infusion schedule is 185 mg/m(2)/day. GTI-2040 appears to have a manageable toxicity profile and is generally well tolerated as a single agent... - Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinomaW M Stadler
University of Chicago, Northwestern University, and Loyola University of Illinois, USA
J Clin Oncol 17:2541-5. 1999..Its highly vascular nature suggests that antiangiogenesis therapy might be useful. We thus performed a phase II study of the fumigillin analog TNP-470 in previously treated patients with metastatic renal cell carcinoma... - Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BH L Kindler
University of Chicago Medical Center, 5841 S Maryland Avenue, Chicago, IL 60637, USA
Lung Cancer 31:311-7. 2001..The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530)... - Emerging insights into the biology and therapy of malignant mesotheliomaNicholas J Vogelzang
University of Chicago Cancer Research Center, Chicago, IL 60637, USA
Semin Oncol 29:35-42. 2002.... - Second-line hormonal therapy for advanced prostate cancer: a shifting paradigmE J Small
Department of Medicine, University of California, San Francisco 94115, USA
J Clin Oncol 15:382-8. 1997..To discuss the evolution of new concepts in the Use of second-line hormonal therapy for patients with progressive prostate cancer despite androgen deprivation... - A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancerAndrew Artz
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637-1470, USA
Am J Clin Oncol 28:109-13. 2005.... - A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinomaC M George
Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637 1470, USA
Ann Oncol 13:116-20. 2002..Based upon in vitro synergy of gemcitabine/cisplatin and 5-FU/cisplatin, we hypothesized that the addition of cisplatin could improve the objective response rate of gemcitabine and 5-FU with manageable toxicity... - Nilutamide: possible utility as a second-line hormonal agentA Desai
Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
Urology 58:1016-20. 2001..CONCLUSIONS: A subset of patients, whose disease progresses with prior antiandrogen therapy, may experience a PSA response to nilutamide. The role of nilutamide in such hormone-resistant patients deserves additional prospective study... - Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan
Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
Clin Cancer Res 10:4406-11. 2004..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies... - Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium studyNancy B Davis
Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
J Clin Oncol 22:115-9. 2004..Insufficient biopsy and whole blood sample numbers preclude conclusions regarding proteasome inhibition within tumor. Further evaluation in this disease setting is not recommended... - Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancerWalter M Stadler
University of Chicago, Illinois 60637, USA
J Urol 170:1141-5. 2003..To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined... - A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancerWalter M Stadler
University of Chicago Phase II Consortium, University of Chicago, Section of Hematology Oncology, Chicago, Illinois 60637, USA
Clin Cancer Res 10:3365-70. 2004..In vitro assessment of SU5416 on PSA secretion was assessed in the LNCaP cell line. Baseline serum basic fibroblast growth factor and plasma vascular endothelial growth factor (VEGF) were explored as prognostic factors... - Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniquesSamuel G Armato
Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
Med Phys 31:1105-15. 2004..93). We have developed computerized techniques for the measurement of mesothelioma tumor thickness in CT scans. These techniques achieved varying levels of agreement with measurements made by human observers... - Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scansSamuel G Armato
Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
Acad Radiol 12:1301-9. 2005..To evaluate the clinical acceptability of semiautomated methods for the measurement of mesothelioma tumor thickness in computed tomography (CT) scans... - Phase I study of an oral formulation of ZD9331 administered daily for 28 daysMichael B Sawyer
Committe on Clinical Pharmacology, Department of Medicine, Cancer Research Center and Section of Hematology/Oncology, University of Chicago, IL USA
J Clin Oncol 21:1859-65. 2003..ZD9331 seems to have a manageable toxicity profile, although it should be used with caution in patients with renal impairment... - Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancerJames O Jin
Section of Hematology Oncology, University of Chicago, IL 60637, USA
Clin Genitourin Cancer 5:150-4. 2006..Despite the general acceptance of gemcitabine/cisplatin in metastatic bladder cancer, its role and tolerability in the adjuvant setting, in which renal insufficiency is common, is unclear... - A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancerChristopher W Ryan
Department of Medicine, Section of Hematology Oncology, University of Chicago MC2115, 5841S Maryland Ave, Chicago, IL 60637, USA
Cancer Chemother Pharmacol 50:1-5. 2002..The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule... - Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumorsRobert J Motzer
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:247-56. 2007..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome... - A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinomaChristopher W Ryan
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
Cancer 94:2602-9. 2002.... - Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B studyEllis G Levine
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263 0001, USA
Cancer 94:665-72. 2002.... - Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancerRichard L Schilsky
Department of Medicine, Section of Hematology Oncology, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Chicago, IL 60637, USA
J Clin Oncol 20:582-7. 2002..The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination... - A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinomaApurva A Desai
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Cancer 95:1629-36. 2002.... - Future directions for gemcitabine in the treatment of genitourinary cancerNicholas J Vogelzang
Department of Medicine and Surgery (Urology, University of Chicago Cancer Research Center, Chicago, IL 60637-1470, USA
Semin Oncol 29:40-5. 2002..These data suggest the need for further trials of gemcitabine alone or in combinations in genitourinary cancer patients... - Variability in mesothelioma tumor response classificationSamuel G Armato
Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
AJR Am J Roentgenol 186:1000-6. 2006..In addition, the performance of a semiautomated measurement method was evaluated... - Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cellsH Harlin
Department of Pathology, The University of Chicago, IL 60637, USA
Bone Marrow Transplant 33:491-7. 2004..Our results support the hypothesis that the antitumor effects of NST may be mediated by IFN-gamma-producing CD8+ T cells, and indicate that isolation of putative tumor antigen-specific T cells, ideally, should be pursued around day +180... - A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinomaAmy C Peterson
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, USA
Invest New Drugs 24:141-9. 2006..CONCLUSIONS: The addition of Bryostatin-1 to IL-2 was well tolerated, but the overall response rate was low (3.2%), indicating that further studies with this combination are not warranted... - Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunctionG F Fleming
Department of Medicine, University of Chicago Medical Center, IL 60637 1470, USA
Ann Oncol 14:1142-7. 2003..Patients with hepatic or renal dysfunction are often treated with 5-fluorouracil (5-FU), but there are few data to confirm the safety of this practice... - Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activityBrian I Rini
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, U.S.A
J Immunother (1997) 25:269-77. 2002.... - Gene expression profiling of renal medullary carcinoma: potential clinical relevanceXiming J Yang
Department of Pathology, The University of Chicago, Chicago, Illinois, USA
Cancer 100:976-85. 2004..The genes that are expressed specifically in this tumor may lead to not only a better understanding of its molecular pathways and discoveries of novel diagnostic markers but also, more important, to effective therapeutic interventions... 
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapyGuru Sonpavde
Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
Cancer 115:4104-9. 2009....- Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumorsSamir D Undevia
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
Invest New Drugs 22:449-58. 2004..The recommended phase II dose is 256 mg/m(2)/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial... - Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinomaMaria S Tretiakova
Department of Pathology, University of Chicago, Chicago, IL 60611, USA
Am J Surg Pathol 28:69-76. 2004.... - A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center StudyW J Gradishar
Department of Medicine, Northwestern University, Chicago, IL, USA
Invest New Drugs 13:171-4. 1995..Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma... - Classification of renal neoplasms based on molecular signaturesXiming J Yang
Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
J Urol 175:2302-6. 2006..Molecular diagnosis appears to be reliable and comparable to the standard of urological pathology. This molecular method may be a potentially useful test for establishing an accurate diagnosis that can impact clinical management... - Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancerWei Peng Yong
Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
Cancer Chemother Pharmacol 60:811-9. 2007..Hence, this study was designed to evaluate if pharmacokinetic modulation of oral etoposide with ketoconazole could lead to a favorable alteration of etoposide pharmacokinetics, and to assess the feasibility and safety of this approach... - A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbitalFederico Innocenti
Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL 60637, USA
Clin Pharmacol Ther 76:490-502. 2004..Five partial responses were observed. Pharmacokinetic modulation of irinotecan with cyclosporine and phenobarbital has been demonstrated; further studies are necessary to evaluate whether this strategy improves the therapeutic index... - Does PC-SPEs interact with warfarin?Nancy B Davis
Department of Pharmaceutical Services and University of Chicago Cancer Research Center, University of Chicago, Illinois, USA
J Urol 167:1793. 2002 - Selecting a secondary treatmentNancy B Davis
Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA
Urol Clin North Am 30:403-14. 2003..ketoconazole. and chemotherapy. At each interval, clinical trials should be offered since none of these maneuvers are proven to prolong life... - Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implicationsJun Sugimura
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Urology 64:362-8; discussion 368. 2004..CONCLUSIONS: The results of our study demonstrated that MN has a distinct gene expression profile and that some of the newly identified genes can be potentially used as novel diagnostic markers... - Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA
J Urol 176:81-6. 2006..We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer... - Activities and accomplishments of the cancer and leukemia group B genitourinary committeeEric J Small
University of California San Francisco, San Francisco, California, USA
Clin Cancer Res 12:3596s-600s. 2006..In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients... - Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480Eric J Small
Comprehensive Cancer Center, University of California San Francisco, 1600 Devisadero Street, Third Floor, San Francisco, CA 94115, USA
J Clin Oncol 20:3369-75. 2002..To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent... - Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical featuresMasayuki Takahashi
Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
Cancer Res 62:6598-605. 2002..In summary, our findings suggest that the integration of gene expression data and clinical parameters could aid in detecting aggressive tumors among favorable histology WT and lead to the discovery of new drugs for WT... - A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastasesPrimo N Lara
University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
Clin Cancer Res 12:1556-63. 2006..Serial serum and urine specimens were collected to assess for markers of bone metabolism... - Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicityChia-Chi Lin
Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan
Cancer 106:1269-75. 2006..The excellent toxicity profile makes it a viable option for patients with poor general conditions. To reach any conclusion, randomized trials comparing P-HDFL with traditional cisplatin-based regimens are necessary... - Treatment options in metastatic renal carcinoma: an embarrassment of richesNicholas J Vogelzang
J Clin Oncol 24:1-3. 2006 - Promising systemic therapy for renal cell carcinomaMatthew M Cooney
Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV 89135, USA
Curr Treat Options Oncol 6:357-65. 2005..A review of the preclinical and early clinical development of some of these novel compounds will be discussed... - Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinomaChia Chi Lin
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
J Urol 177:84-9; discussion 89. 2007..We tested the efficacy and toxicity of adding paclitaxel to that regimen... - The emerging role of antifolates in the treatment of malignant pleural mesotheliomaKarim Fizazi
Institut Gustave Roussy, Villejuif, France
Semin Oncol 29:77-81. 2002..In both trials, survival is the main endpoint. These trials will help to define the role of these new antifolates in malignant pleural mesothelioma... - Chemotherapy for malignant pleural mesotheliomaNicholas J Vogelzang
Nevada Cancer Institute, Las Vegas, Nevada 89135, USA
Lancet 371:1640-2. 2008 
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904Robert A Kratzke
Division of Hematology Oncology Transplant, The University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Thorac Oncol 3:417-21. 2008..This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16INK4a via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC)...- Second-line chemotherapy for advanced hormone-refractory prostate cancerEdward G Garmey
ArQule Inc, Woburn, MA 01801 5140, USA
Clin Adv Hematol Oncol 6:118-22, 127-32. 2008..To date, only one phase III randomized clinical trial has been completed in this setting and no therapies are FDA-approved. We review here the entirety of phase II and III data evaluating chemotherapy agents in second-line HRPC... - Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibitionDuyen T Dang
Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Cancer Res 68:1872-80. 2008..The data further show that DPP4 is a novel marker of HIF-1 induction. Altogether, these preclinical findings suggest novel clinical trials for predicting and monitoring tumor vessel responses to antiangiogenic therapy... - Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancerSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27705, USA
Cancer 110:1478-84. 2007..For this reason, the correlation between an elevated body mass index (BMI) and clinical outcomes in patients with metastatic, castration-recurrent prostate cancer (CRPC) was evaluated... - Signal-transduction inhibitors in renal cell carcinomaNicholas J Vogelzang
Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV, USA
BJU Int 99:1289-95. 2007 - Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 25:1596-605. 2007..To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa)... - Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesotheliomaStanislaw M Mikulski
Alfacell Corp, 225 Belleville Ave, Bloomfield, NJ 07003, USA
J Clin Oncol 20:274-81. 2002..Patients with unresectable and histologically confirmed malignant mesothelioma (MM) were eligible... - Standard therapy for the treatment of malignant pleural mesotheliomaNicholas J Vogelzang
Nevada Cancer Institute, Las Vegas, NV 89135, USA
Lung Cancer 50:S23-4. 2005..This doublet-based chemotherapy regimen is now the standard therapy for the first-line treatment of MPM... - Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancersCora N Sternberg
Department of Medical Oncology, San Camillo and Forlanini Hospitals, 00152, Rome, Italy
Crit Rev Oncol Hematol 46:S105-15. 2003..The molecular biology of these diseases is being unravelled and as knowledge accumulates, our ability to target these cancers will continue to increase... - A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh
Lank Center for Geritourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 98:2592-8. 2003..The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma... - Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitorJohn L Marshall
Georgetown University Medical Center-Lombardi Cancer Center, Washington, DC 20007, USA
Invest New Drugs 23:31-7. 2005..Further study is necessary to determine the clinical efficacy of this novel new chemotherapeutic agent... - Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480Tim A Ahles
Norris Cotton Cancer Center, Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
Cancer 101:2202-8. 2004..The primary purpose of the current study was to evaluate whether there was evidence of palliative effects associated with suramin at any of the three doses administered in the original clinical trial... - A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated?Matthew M Cooney
Division of Hematology Oncology, University Hospitals of Cleveland, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
Curr Urol Rep 5:19-24. 2004..Even with this aggressive approach, most patients eventually will die from their kidney cancer; therefore, every patient with metastatic disease should be considered for enrollment into clinical trials... - Impact of race on survival in men with metastatic hormone-refractory prostate cancerSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
Urology 64:212-7. 2004..71 to 1.02, P = 0.08) for blacks compared with whites. CONCLUSIONS: No statistically significant difference was found in overall survival between blacks and whites with metastatic hormone-refractory prostate cancer... - Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of actionMario A Eisenberger
Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 1000, USA
Urology 63:114-9. 2004..To study the safety, pharmacokinetics, biologic activity, and preliminary efficacy of the bispecific 5-alpha-reductase inhibitor (LY320236) in prostate cancer... - Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancerCelestia S Higano
University of Washington Medical Center, Seattle, Washington 98109, USA
Clin Cancer Res 10:1219-25. 2004..In the first cycle, patients were randomized to FL or placebo. All patients received open-label FL during the next five courses. DC, anti-FL antibody, and PSA levels were measured every 15 days to assess biological activity... - Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerEric K Rowinsky
Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Rd, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
J Clin Oncol 22:3003-15. 2004.... - Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesotheliomaNicholas J Vogelzang
Clin Lung Cancer 5:63-4. 2003 - Multimodality therapy in mesothelioma: role of chemotherapyNicholas J Vogelzang
Nevada Cancer Institute, 10, 000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135, USA
Thorac Surg Clin 14:531-42. 2004.... - The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480Daniel J George
Divisions of Urology and Medical Oncology, Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 2771, USA
Clin Cancer Res 11:1815-20. 2005..In order to evaluate its prognostic significance in metastatic HRCaP patients, we measured IL-6 in plasma collected at baseline from patients in a large cooperative group study [Cancer and Leukemia Group B 9480 (CALGB 9480)]... - Novel agents for the treatment of advanced kidney cancerMatthew M Cooney
Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
Clin Adv Hematol Oncol 2:664-70. 2004..These compounds include antiangiogenic agents, raf kinase pathway inhibitors, and novel antimicrotubule agents. This review discusses some of the agents currently being explored for the treatment of advanced kidney cancer... - A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapyNancy B Davis
Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI, USA
BJU Int 96:787-90. 2005..To determine the prostate-specific antigen (PSA) response and time to PSA or radiographic progression in men with prostate cancer refractory to bicalutamide and/or flutamide therapy... - Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary Ellen Taplin
University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
J Clin Oncol 21:2673-8. 2003..Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation. Materials and.. - New agents in the management of advanced mesotheliomaNicholas J Vogelzang
Nevada Cancer Institute, Las Vegas, NV 89135, USA
Semin Oncol 32:336-50. 2005..Together with the newer drugs, rapidly emerging from the laboratory to be applied in the clinic, we have the hope of making further advances in the struggle against this disease... - A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancerChristopher W Ryan
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
BJU Int 95:963-8. 2005.... - Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerH Barton Grossman
M.D. Anderson Cancer Center, Houston, USA
N Engl J Med 349:859-66. 2003.... - Molecular subclassification of kidney tumors and the discovery of new diagnostic markersMasayuki Takahashi
Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA
Oncogene 22:6810-8. 2003..We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications... - Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancerSusan Halabi
J Clin Oncol 23:2434-5; author reply 2435. 2005 - Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)Eric J Small
UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
J Clin Oncol 22:1025-33. 2004..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...